Anemia during pregnancy and the postpartum period is commonly caused by iron deficiency and is a significant worldwide issue with severe consequences for both mother and developing fetus. From a worldwide perspective, iron-deficiency anemia (IDA) during pregnancy is highest in the Asia-Pacific region; however, there has been little guidance in this region for safe and effective treatment. An expert panel was convened to develop a concise and informative set of recommendations for the treatment of IDA in pregnant and postpartum women in the Asia-Pacific region. This manuscript provides these recommendations and aims to reduce the morbidity and mortality associated with IDA in pregnant and postpartum women in the Asia-Pacific region. The consensus recommendations define anemia as a hemoglobin (Hb) level -10.5 g/dL during pregnancy and -10 g/dL during the postpartum period, and provide cut-off Hb levels to 
Introduction
Anemia is one of the most prevalent diseases worldwide, affecting 24.8% of the human population (1.62 billion people) (Table 1) , and is a major health concern w3, 29x. Iron shortage is the single most common nutritional deficit in the world w3, 8x and is the major cause of anemia, accounting for approximately 50% of cases w28, 29x. The prevalence of iron-deficiency anemia (IDA) varies among countries but is a particular problem in the developing world, reflecting differences in race, socio-economic factors, nutritional habits, medical care and the frequency of parasitic illnesses w8x. Numerous countries conduct interventions to reduce anemia, particularly in susceptible groups, such as pregnant women and young children.
Anemia during pregnancy is a significant concern with the World Health Organization (WHO) estimating a prevalence of 41.8% amongst pregnant women (Table 1) w29x. Iron demand increases rapidly in the second and third trimester of pregnancy with the needs of the developing fetus, with a daily requirement of up to 10 mg w21x. Iron absorption from the diet also increases during pregnancy through upregulation of iron transporters in the gut w19x; however, this increase in absorption is not sufficient to meet the demand during the latter stages of pregnancy. Therefore, iron balance depends largely upon maternal iron stores w8, 9x. A pre-pregnancy store of more than 500 mg of iron is required to avoid iron deficiency during pregnancy, yet such adequate levels of iron are only present in 20% of menstruating women before pregnancy ensues w3x. These iron store deficits are exacerbated by the blood loss experienced during the delivery process and add to the considerable risk of developing postpartum anemia w9x.
The consequences of IDA during pregnancy are often serious and long lasting for both the mother and fetus w8, 22x (Table 2) . Expectant mothers with anemia often experience increased fatigue levels, reduced exercise performance and reduced mental performance w8, 22x. Furthermore, severe anemia whemoglobin (Hb) -9 g/dLx is related to an increased risk of prematurity, small for gestational-age babies and spontaneous abortion w8x. Fetal iron metabolism is com- 
Pregnancy
• Oral iron in patients with mild-to-moderate IDA • Oral iron in first and second trimester (Hb 9-10.5 g/dL)
• Consider i.v. iron after 14 weeks' gestation • I.v. iron in second and third trimester in patients:
in patients unresponsive to oral iron -Unresponsive to oral iron (Hb increase -0.5 g/dL in 2 weeks) -With severe IDA (Hb -9 g/dL)
• I.v. iron in third trimester in case of IDA -With other factors such as requirement for
• If available, test serum ferritin for iron stores rapid repletion (Jehovah's Witnesses etc) Postpartum • Oral iron in patients with mild anemia
• Without ongoing bleeding (Hb 9.5-12 g/dL)
• I.v. iron if Hb 6-9.5 g/dL • I.v. iron in moderate-to-severe anemia -ESA can be used in non-responders (Hb 8.5-9.5 g/dL)
• Oral iron, administered in the form of ferrous sulphate, ferrous fumerate, ferrous gluconate or iron hydroxide polymaltose complex, is considered the current standard for the treatment of IDA and is most commonly prescribed in cases of mild-to-moderate anemia w8, 9x. The benefits of oral iron intervention include ease of use since no medical expertise is required for administration. However, limited efficacy and low patient compliance are often an issue, particularly due to gastrointestinal side effects w18, 20x. As such, oral iron may take a long time to correct IDA. Moreover, among the different oral iron preparations, ferrous salts, but not a polysaccharide-ferric iron complex lead to oxidative stress as evidenced by increased levels of non-transferrin bound iron (or NTBI) w14x.
I.v. iron
The use of i.v. iron to treat IDA in pregnant women was first examined almost 60 years ago; enhanced Hb levels following Reproduced with permission from the World Health Organization, CIsconfidence interval; WHOsWorld Health Organization. i.v. iron sucrose administration were demonstrated while iron not utilized by the hematopoietic tissues helped replenish maternal iron stores w17x. More recent studies have demonstrated i.v. iron to be more efficient than oral iron at increasing Hb levels and replenishing iron stores w1, 4, 6x. The recently published recommendations for the treatment of IDA in pregnancy include i.v. iron as an effective alternative to oral iron during the second and third trimester for pregnant women who fail to respond to oral iron therapy w10x (Table 3) . I.v. iron preparations include iron sucrose, sodium ferric gluconate, low molecular weight iron dextran and newer ''next generation'' preparations, such as ferric carboxymaltose w10x; however, these preparations have substantially different safety profiles w2x. For example, dextran-containing i.v. iron preparations have been shown to be associated with an increased risk of anaphylactic reactions w2x, whilst iron sucrose and sodium ferric gluconate are associated with fewer side effects w2x. Furthermore, subtle structural variations between the iron sucrose formulations produced by different manufacturers may affect the stability of the iron complex and, in turn, the safety and efficacy profile w26x.
Additionally, numerous studies have demonstrated the efficacy and safety of i.v. iron sucrose in pregnant (second and third trimester) w1, 12x and postpartum women w6, 10x. Experience with i.v. iron sucrose in the Asia-Pacific region is growing w16, 24, 27x and data are comparable to results from European studies w6, 12x, demonstrating that i.v. iron sucrose is effective, provides rapid correction of anemia and is well tolerated in treating IDA during pregnancy w16, 24, 27x.
Packed cells or red blood cell transfusion
Although blood transfusions are an effective treatment for IDA, since they deliver exactly what the body needs (red blood cells) without any further physiological effort, they do not correct the underlying cause of anemia. Furthermore, there are many inherent risks involved with this treatment, including serious infection, incorrect transfusion, negative impact on the immune system and transfusion reactions w7, 13x. Additionally, certain groups of the population may refuse blood transfusions due to religious beliefs, and limited blood supply often means that stock is reserved for emergencies. Therefore, the administration of a blood transfusion should be considered as a last resort when a patient is unresponsive to i.v. iron supplementation or is in a critical condition.
Managing IDA in pregnant and postpartum women in the Asia-Pacific region -present situation
The prevalence of anemia during pregnancy and the postpartum period is a particular problem in the Asia-Pacific region where it is the highest worldwide. In Southeast Asia and the Western Pacific, 48.2% and 30.7% of pregnant women have anemia, but some data indicate that prevalence could be as high as 85.6% and 90.2%, respectively w29x (Table 4) . In this region, oral iron and blood transfusions are currently the most common therapies for the treatment of IDA (Table  5) . However, these strategies are suboptimal since oral iron is slow to increase Hb to desired levels in moderate-to-severe anemia. Moreover, a limited availability of blood donors, high costs and risk of infection means that blood transfusions should only be used sparingly in very serious cases w7, 13x. It is, therefore, vital that effective guidelines for the treatment of IDA in pregnancy are developed for the Asia-Pacific region to ensure prompt intervention and optimal care of the mother and developing fetus.
Physicians throughout the Asia-Pacific region face a range of unique challenges when managing IDA in pregnant and postpartum women (Table 6 ). In some areas, testing for and treatment of anemia during pregnancy are not a priority since there is an acceptance that anemia is commonplace in the general population accompanied by a lack of perception of the consequences of maternal IDA. Also, the high prevalence of thalassemia and malaria in some regions complicates diagnosis and treatment; therefore, identifying the cause of anemia is essential before intervention is initiated. Access to the appropriate therapy is often an issue with geographic and economic barriers, preventing optimal care of patients in greatest need.
Evidence of the efficacy and safety of i.v. iron as a treatment for IDA is growing through a number of international trials w1, 4, 6, 10, 12, 15, 16x. These studies have shown a rapid correction of anemia and a reduced risk of blood transfusions in the peripartum and postpartum period. As a result, the use of i.v. iron as a treatment for IDA has increased in Europe in the obstetric/gynecologic setting. Similar studies at the local level in the Asia-Pacific region have been lacking and consequently the use of i.v. iron in this region has been limited. Other issues including fear of adverse events, availability of resources and economic viability (Table 6 ) also restrict the use of i.v. iron in these communities. However, intervention with i.v. iron is expected to grow in the AsiaPacific region in parallel with evidence from recent trials conducted in this section of the population w16, 24, 27x.
Recommendations for diagnosis and treatment of IDA in pregnancy in the Asia-Pacific region Accepted guidelines to assist physicians treating pregnant women with IDA are lacking in the Asia-Pacific region. An expert panel (Appendix), of physicians involved in the treatment of anemia in the obstetrics/gynecology setting and with long-term experience of iron therapy, was convened to develop a concise and informative set of recommendations for the treatment of IDA in pregnant and postpartum women in the Asia-Pacific region. This manuscript provides these recommendations and aims to raise awareness of the safety and efficacy of treatments available for IDA to meet the requirements of pregnant and postpartum women in the AsiaPacific region.
Diagnosis of IDA during pregnancy in the Asia-Pacific region
Anemia in pregnancy is defined by the Center for Disease Control and Prevention as an Hb level of below 11 g/dL in the first and third trimester and an Hb below 10.5 g/dL in the second trimester w23x; likewise, the WHO define anemia in pregnancy as an Hb level below or equal to 11 g/dL w29x. The Hb cut-off levels currently used in practice are often lower than these levels (Table 5) ; hence, it is important to raise awareness of the criteria used for the diagnosis of anemia in pregnant women. A hematologic profile, including Hb levels and hematocrit, enables the diagnosis of anemia w8x and biochemical markers of iron levels are important for determining the cause of anemia before treatment is initiated. To identify IDA, both Hb (an indicator of anemia) and serum ferritin (an indicator of iron storage) should be assessed: low ferritin levels indicate iron deficiency, while normal-to-high ferritin levels can indicate thalassemia, lead poisoning and inflammation w25x. Therefore, the appropriate use of markers for iron levels should be established to aid the diagnosis of IDA during pregnancy and the postpartum period. Due to the serious consequences of IDA in pregnancy, prompt and effective intervention is required (Tables 2 and  3) . It is important to note that i.v. iron and oral iron are only licensed for the treatment of iron deficiency. Furthermore, the use of i.v. iron is contraindicated during the first trimester of pregnancy. However, the use of i.v. iron is considered safe in the second and third trimester w20x. It is, therefore, advisable to check the labels for both oral and i.v. iron compounds prior to their administration. The consensus recommendations (Figures 1 and 2 ) target the application of oral iron, i.v. iron and blood transfusion to specific severities of IDA (stratified by Hb level) to ensure the safest and most efficient treatment possible. The Hb cut-off values were agreed by the expert panel to indicate the need for treatment of IDA during pregnancy (Figure 1 ) and the postpartum period (Figure 2 ).
Areas requiring further consideration
Recent studies have demonstrated the efficacy and safety of i.v. iron in pregnant (second and third trimester) w1, 4, 12x and postpartum women w6, 12x. Experience with i.v. iron in the Asia-Pacific region is growing w16, 24, 27x. However, further studies in this region are warranted to enhance confidence in the use of i.v. iron among prescribing physicians.
Measures to raise awareness of the consequences of IDA are also required to ensure the appropriate testing and prompt treatment of anemia during pregnancy and the postpartum period.
Conclusions
IDA is the most frequent form of anemia during pregnancy and can have serious consequences for both the mother and fetus. The majority of women do not have adequate iron stores to meet the dramatic increase in requirements during the second and third trimester of pregnancy. From a worldwide perspective, IDA in pregnancy is highest in the AsiaPacific region; however, there has been little guidance in this region for the safe and effective treatment of IDA during pregnancy and the postpartum period. Currently, the main interventions in this region are oral iron and blood transfusions. However, i.v. iron is more effective, provides more rapid Hb correction, corrects iron stores and is better tolerated than oral iron in treating IDA during pregnancy w1, 4, 10x. Furthermore, recent studies have demonstrated the efficacy and safety of i.v. iron in the second and third trimester of pregnancy w1, 4, 10x and in postpartum women w6, 10x. The goal of the recommendations presented here is to reduce the morbidity and mortality associated with IDA in pregnant and postpartum women in the Asia-Pacific region. Consensus recommendations include a definition of anemia as an Hb level below 10.5 g/dL in pregnancy and below 10 g/dL in the postpartum period. The panel also advocates the use of i.v. iron in the second and third trimester of pregnancy to correct anemia and reduce the risk of transfusion in the postpartum period. Further randomized phase III trials with i.v. iron in the Asia-Pacific region are warranted to optimize clinical outcomes for the mother and developing fetus.
